Top Markets
Coin of the day
Medlab Clinical Limited Medlab Clinical Limited

Medlab Clinical Limited

MDC
Kedudukan dalam Saham #32244
Medlab Clinical Limited is an Australian biotechnology firm dedicated to the... Medlab Clinical Limited is an Australian biotechnology firm dedicated to the research, development, and initial commercialization of innovative pharmaceutical and nutraceutical products. Its pipeline features key drug candidates such as NanaBis, a buccal spray derived from cannabis oil extract, intended for use in oncology and pain management. Another significant candidate is NanoCBD, a buccal spray sourced from hemp oil extract, aimed at supporting mental well-being. A core innovation is NanoCelle, a proprietary sub-micron drug delivery platform that enables the direct passive diffusion of active pharmaceutical ingredients into the bloodstream through diverse administration methods including oral-buccal, sublingual, intranasal, and transdermal or topical applications. The company also extends its offerings to include virtual clinic services. Founded in 2012, Medlab Clinical Limited is headquartered in Botany, Australia.
Harga Saham
$4.65
Disegerakkan terakhir: 2024-07-24
Modal Pasaran
$10.63M
Perubahan (1 hari)
6.66%
Perubahan (1 tahun)
0.00%
Negara
AU
Perdagangan Medlab Clinical Limited (MDC)

Kategori

Pendapatan untuk Medlab Clinical Limited (MDC)
Pendapatan pada 2026 TTM: 0
Menurut laporan kewangan terkini Medlab Clinical Limited, pendapatan semasa syarikat ialah 0. Pada tahun 2026, syarikat memperoleh pendapatan sebanyak 0, sama dengan pendapatan pada tahun 2026 yang berjumlah 0. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Medlab Clinical Limited dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
Tidak cukup data untuk tarikh yang disediakan.
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
$5.27B -
US
$1.95B -
NL
$1.61B -
AU
- -
CH
- -
KR